Product Program year 2020 Source: CMS Open Payments

Pradaxa

Drug Cardiovascular

NDC 0597-0135-54

Open in the dashboard

General payments

$908,622

22,868 payments

Research payments

$3,365,604

412 payments

Through program year 2020, $908,622 in general payments and $3,365,604 in research payments were reported against Pradaxa (Cardiovascular).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

4 rows
Year Kind Amount Payments
2020 General $162,508 5,193
2020 Research $770,062 130
2019 General $746,114 17,675
2019 Research $2,595,542 282

Breakdown

Who paid General payments · program years 2019–2020
  1. Boehringer Ingelheim Pharmaceuticals, Inc. $908,622 22,868 payments
Top recipients General payments · program year 2020
  1. Providence Portland Medical Center Teaching hospital · OR $27,411 17% · 4 payments
  2. Richard Wright Advanced Heart Failure and Transplant Cardiology · Santa Monica, CA $12,186 7% · 4 payments
  3. Raymond Resnick Interventional Cardiology · Williamsport, PA $2,624 2% · 3 payments
  4. Nedaa Skeik Cardiovascular Disease · Minneapolis, MN $2,600 2% · 2 payments
  5. Arnold Einhorn Cardiovascular Disease · Orlando, FL $2,080 1% · 1 payment

The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2020.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2020
  1. Cardiovascular Disease Internal Medicine $69,002 53% · 1,533 practitioners
  2. Interventional Cardiology Internal Medicine $21,028 16% · 504 practitioners
  3. Advanced Heart Failure and Transplant Cardiology Internal Medicine $13,189 10% · 22 practitioners
  4. Clinical Cardiac Electrophysiology Internal Medicine $10,297 8% · 147 practitioners
  5. Internal Medicine $7,625 6% · 242 practitioners

The top 5 of 38 specialties; each share is of general payments naming this product to practitioners with a specialty in 2020. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2020
  1. Oregon $27,781 17% · 18 recipients
  2. California $23,791 15% · 250 recipients
  3. Florida $18,506 11% · 347 recipients
  4. New York $11,885 7% · 245 recipients
  5. Pennsylvania $8,128 5% · 160 recipients

The top 5 of 45 states; each share is of general payments naming this product in 2020 where a state was reported.

The top 25 states, free in the app

Prescribed to Medicare patients

Part D · data year 2024

Part D claims

409,643

Prescriptions dispensed, refills included

Drug cost

$103,383,213

Paid at the pharmacy, in all

Prescribers

7,474

With 11 or more claims of it

Medicare Part D drugs matched to PRADAXA, 2024
Part D drug Name match Relative to the largest Prescribers Claims Drug cost
Pradaxa Dabigatran Etexilate Mesylate Same name 7,474 409,643 $103,383,213

Matched to this product by name; CMS does not link its files to Open Payments, so a similar name can be a different strength, form or brand. Prescriber counts include only prescribers with 11 or more claims of the drug, because CMS publishes nothing below that. Part D covers drugs dispensed to Medicare beneficiaries at a pharmacy; it does not include drugs given in a clinic or hospital, or patients with other insurance.

Largest prescribers

First 5 of 100 by claims · 2024

Two separate records. Claims come from Medicare and related payments from Open Payments. They are shown in one row because they name the same product; they do not show that a payment affected a prescription.

The prescribers with the most Part D claims of this drug in 2024
Prescriber Specialty State Claims Drug cost Related payments
Jennifer Tresser Pharmacist CA 14,721 $4,197,227 No profile
Huong Ha Pharmacist CA 11,777 $3,395,713 No profile
Carmen Wong Pharmacist CA 9,892 $2,851,484 No profile
Jordan Wong Pharmacist CA 8,618 $2,509,085 No profile
Hyeon Hye Lee Pharmacist CA 7,632 $2,202,146 No profile

"No profile" means the prescriber has no Open Payments record here; "None on record" means no payment naming this product in the payment year. Related payments are general payments, and one that names several products is split evenly, so an amount is payments related to the product, not money paid for it. The list is the prescribers with the most claims, up to 100 per drug.

See more in the dashboard: 25 with a free account, all 100 with Patron
22,868 general · 412 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2020

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record